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Background: In recent years, the rapidly advancing field of low-temperature atmospheric pressure plasmas has shown
considerable promise for future translational biomedical applications, including cancer therapy, through the generation of
reactive oxygen and nitrogen species.
Method: The cytopathic effect of low-temperature plasma was first verified in two commonly used prostate cell lines: BPH-1 and
PC-3 cells. The study was then extended to analyse the effects in paired normal and tumour (Gleason grade 7) prostate epithelial
cells cultured directly from patient tissue. Hydrogen peroxide (H2O2) and staurosporine were used as controls throughout.
Results: Low-temperature plasma (LTP) exposure resulted in high levels of DNA damage, a reduction in cell viability, and colony-
forming ability. H2O2 formed in the culture medium was a likely facilitator of these effects. Necrosis and autophagy were recorded
in primary cells, whereas cell lines exhibited apoptosis and necrosis.
Conclusions: This study demonstrates that LTP treatment causes cytotoxic insult in primary prostate cells, leading to rapid
necrotic cell death. It also highlights the need to study primary cultures in order to gain more realistic insight into patient
response.
Despite continual improvement and refinement, long-term
treatment for prostate cancer (PCa) is still recognised as inadequate
(Jemal et al, 2011). In the case of early onset, organ-confined tumours,
patients may be treated with a focal therapy (Kasivisvanathan et al,
2013; Donaldson et al, 2014). Radiotherapy or photodynamic therapy
(PDT), which rely on the production of reactive oxygen species (ROS)
for cytotoxic effects, are two treatments of choice for localised PCa.
However, around a third of patients will experience recurrence of
their disease following radiotherapy (Jones, 2011). This may be due to
inherent radio-resistance of a small fraction of the tumour – the
cancer stem-like cells (Frame et al, 2013). Furthermore, numerous
side effects are often experienced following treatment (Chen et al,
2007; Lips et al, 2008), even with more recent technological
developments, such as stereotactic body radiation therapy (Cyber-
knife) (Woo et al, 2014).
In recent years, low-temperature plasmas (LTPs) have shown
considerable potential as active agents in biomedicine. They are
formed by applying a high electric field across a gas, which accelerates
electrons into nearby atoms and molecules, leading to a cascade effect
of multiple ionisation, excitation and dissociation processes. This
creates a complex and unique reactive environment consisting of
positive and negative charges, strong localised electric fields, UV
radiation, reactive species, and mainly background neutral molecules.
Operated at atmospheric pressure and around room temperature,
LTPs produce high concentrations of reactive oxygen and nitrogen
species (RONS), including but not limited to: atomic nitrogen
(Wagenaars et al, 2012) and oxygen (Knake et al, 2008; Waskoenig
et al, 2010; Niemi et al, 2013), hydroxyl (OH) (Ninomiya et al, 2013),
singlet delta oxygen (SDO) (Sousa et al, 2011), superoxide (Kang et al,
2014), and nitric oxide (NO) (Ma et al, 2014). It is now widely
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believed that the principal mode of plasma–cell interaction is the
delivery of RONS, a key mediator of oxidative damage and cell death
in biological systems (Wiseman and Halliwell, 1996; Bandyopadhyay
et al, 1999), generated in the plasma and transferred to target source
(Graves, 2012, 2014).
In contrast, cell death by PDT relies on the generation of ROS,
specifically SDO, which is highly cytotoxic (Sharman et al, 1999).
Nonetheless, strong treatment resistance is encountered in hypoxic
tumour regions (Krzykawska-Serda et al, 2014). The limitations of
both radiotherapy and PDT, combined with the fact that LTPs
concurrently produce both a multitude of RONS (Murakami et al,
2013) known to be toxic to cells and potentially strong localised
electric fields, promotes the potential of LTP as a future cancer
therapy, which we have recently reviewed (Hirst et al, 2014b).
Many studies now describe the effects of LTPs on various cancer
cell lines in culture, with reported effects including reduced cell
viability (Cheng et al, 2014; Plewa et al, 2014), growth arrest
(Chang et al, 2014), and apoptotic cell death (Keidar et al, 2011;
Gibson et al, 2014; Ishaq et al, 2014). We have reported induction
of DNA damage by application of LTP treatment to primary
prostate epithelial cells (Hirst et al, 2014a). Recent in vivo studies
also revealed that LTP treatment of subcutaneous tumours (grown
from cell lines) induced growth arrest and cell death, thus
significantly reducing tumour volume in glioblastoma cells
(Vandamme et al, 2012). Another study showed that short, daily
exposure of tumours (squamous cell carcinoma) to LTP causes
DNA damage leading to apoptosis (Kang et al, 2014). Internal
treatment with LTP has also been explored using an endoscopic
approach to application (pancreatic and colorectal cells), which
demonstrated reduced tumour volume and also invasion capacity
(Robert et al, 2013). However, the penetrative capability of LTP
treatment through solid tissues leading to complete tumour
eradication is yet to be established in vivo.
Here we first conducted a proof-of-principle study in order to
validate the cytopathic effect of LTP treatment on two commonly
used prostate cell lines derived from benign disease (BPH-1) and
prostate cancer metastasis (PC-3). We then analysed in detail the
effect of LTP treatment on a matched pair of primary samples. We
cultured prostate epithelial cells from normal prostate and prostate
cancer tissue (Gleason grade 7) retrieved from biopsies from a
single patient, allowing for direct comparison of the effects of LTP
on both normal and cancer cells. We present the first experimental
evidence that LTP may be a suitable candidate for focal therapy
treatment of patients with early onset prostate cancer through the
induction of high levels of DNA damage, leading to a substantial
reduction in colony-forming capacity, and ultimately necrotic cell
death, in clinically relevant and close-to-patient samples.
MATERIALS AND METHODS
Culture of cell lines and primary prostate epithelial cells. Two
prostate cells lines were used in this study: BPH-1 cells, derived
from benign prostatic hyperplasia (BPH), and PC-3 cells, derived
from PCa bone metastases. BPH-1 cells were cultured in RPMI
1640 medium supplemented with 5% foetal calf serum (FCS) and
1% L-glutamine. PC-3 cells were cultured in Ham’s F12 medium,
supplemented with 7% FCS and 1% L-glutamine. No antibiotic or
antimycotics were added to the cell culture medium. Cells were
incubated at 37 1C with 5% CO2.
Primary prostate epithelial cells were cultured from human
tissue samples as described previously (Collins et al, 2005). Needle
core biopsies (14 g) were taken immediately following surgical
removal of the prostate. The site of each biopsy was determined
by previous pathology, imaging, and palpation. Tissues were
transported in RPMI-1640 with 5% FCS and 100Uml 1
antibiotic/antimycotic solution at 4 1C and processed within 6 h.
Needle core biopsies were verified as normal or Gleason grade 7
cancer by subsequent pathology, both cores originating from the
same patient undergoing radical prostatectomy. Samples were
obtained with full ethical permission and patient consent. Primary
cells were cultured in stem cell media, based on keratinocyte
serum-free media supplemented with L-glutamine, stem cell factor,
granulocyte macrophage colony stimulating factor, cholera toxin,
bovine pituitary extract, epidermal grown factor and leukaemia
inhibitory factor (Collins et al, 2005). Significantly, these cells are
cultured in media without FCS. Cells were grown on collagen-I-
coated 10-cm dishes in the presence of irradiated STO feeder cells
and incubated at 37 1C with 5% CO2. No antibiotic or antimycotics
were added to the cell culture medium.
LTP jet configuration and characterisation. The LTP jet
consisted of a quartz glass tube of inner/outer diameter 4/6mm,
with two copper tape electrodes spaced 20mm apart (Figure 1A).
One electrode was powered (6 kV sinusoidal voltage at 30 kHz) and
one grounded. Helium was used as a carrier gas at 2 standard litres
per minute (SLM), fed with 0.3% molecular oxygen admixture.
Cells were exposed to the LTP jet at a distance 15mm from the end
of the bottom electrode for a range of treatment times from 0 to
600 s in centrifuge tubes in a volume of 1.5ml media. The distance
between the end of the glass tube and the media surface
was B2mm. Hydrogen peroxide (H2O2, Fisher Scientific,
Loughborough, UK) was used throughout as a positive cytoxicity
control at a concentration of 1mM. Using a thermocouple,
treatment times of up to 600 s did not raise the surface temperature
of culture media above 36.5 1C. The temperature and relative
humidity of the laboratory were B20 1C and B25% respectively.
Optical emission spectroscopy was performed using an Ocean
Optics HR4000CG-UV-NIR spectrometer (Dunedin, FL, USA)
(200–1100 nm range) and the Spectra suite analysis software
(Dunedin, FL, USA). Integration time and scans to average were
set at 6 and 50 s, respectively. A background dark spectrum was
obtained and subtracted from subsequent spectra. The optical fibre
was aligned directly with the core plasma region and fixed at
B2 cm from the quartz tube.
Cell viability and clonogenic recovery assays. Cell viability was
determined by use of the alamarBlue assay (Invitrogen, Life
Technologies Ltd, Paisley, UK). Cells were treated with LTP and
then plated into black-walled 96-well plates in triplicate at a density
of 5000 cells per well in 100 ml of media. At 24, 48, 72, and 96 h
after treatment, 10 ml of alamarBlue reagent (DAL1025, Invitrogen)
was added to each well and incubated for 2 h at 37 1C. Fluorescence
was recorded at excitation/emission values of 544/590nm using a
microplate reader (Polarstar Optima, BMG Labtech, Aylesbury,
Bucks, UK), with cell viability recorded against normalised
untreated samples.
Clonogenic recovery assays were used to measure cellular
recovery posttreatment. Cells were treated in suspension and
replated in six-well plates in triplicate at a density of 200
disaggregated cells per well. Cells were supplemented with 2ml
of growth media, which was changed every other day. In the case of
primary epithelial cell cultures, STO feeder cells were also added.
At 12 days after treatment, plates were stained with crystal violet
(PBS, 1% crystal violet, 10% ethanol). Only colonies of 450 cells
(equating to 45 population doublings) were counted (Francipane
et al, 2008).
DNA damage. LTP-induced DNA damage was quantified using the
alkaline comet assay (adapted from Sturmey et al, 2009). Cells were
treated with LTP in 1.5ml centrifuge tubes at a density of 20 000
cells in 1.5ml media suspension. Immediately after treatment, cells
were resuspended in 30ml PBS and mixed with 225ml low melting
point agarose. This was then pipetted onto microscope slides
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precoated with high melting point agarose and placed into lysis
buffer (2.5M NaCl, 10mM Tris, 1mM EDTA, 10% DMSO, 1%
Triton X-100), overnight at 4 1C. The following day, cells were
placed in alkaline buffer (0.3M NaOH, 1mM EDTA, pH 13) on ice
for 40min, before being electrophoresed at 23–25V, 300mA in
alkaline buffer for a further 40min on ice. Slides were then placed
into neutralising buffer (0.4M Tris, pH 7.5) for 2 10min, before
DNA was stained using SYBRgold (1 : 10 000 in TE buffer: 10mM
Tris, 1mM EDTA, pH 7.5). Images were acquired by fluorescence
microscopy (Nikon Eclipse TE300 microscope (Nikon, Surrey, UK),
 10 objective lens) using Volocity software (Volocity 6.3,
PerkinElmer Inc., Waltham, MA, USA). Autocomet software (Tritek
Corp., Sumerduck, VA, USA) was used to analyse cell images, with
the median percentage of DNA-in-tail values used to record DNA
damage in a minimum of 100 cells per treatment.
Detection of ROS. Extracellular H2O2 formed in the culture
media as a result of LTP treatment was detected and quantified
using the ROS-Glo H2O2 assay (Cat. no. G8820, Promega,
Southhampton, UK). Cells were treated with LTP, before being
plated into black-walled 96-well plates at a density of 10 000 cells in
80 ml of culture media, before following the manufacturer’s
protocol. Luminescence intensity was quantified using a microplate
reader (Polarstar Optima, BMG Labtech) and normalised to
untreated wells.
Western blotting. Cells were collected at 2, 4, 8, and 24 h
following LTP treatment, and protein lysates were extracted using
Cytobuster Protein Extraction Reagent (71009, EMD Millipore,
Darmstadt, Germany) with protease inhibitors (cOmplete, EDTA-
free Protease Inhibitor Cocktail Tablets, Roche Applied Science,
Burgess Hill, West Sussex, UK). Primary antibodies included:
cleaved-PARP (Asp214, 1 : 666, Cell Signalling Technology Inc.,
Hitchin, UK; no. 9541S), anti-LC3B (Ab51520, Abcam, Cambridge,
UK; 1 : 3000), and monoclonal anti-b-actin 1 : 5000 (A5316, Sigma-
Aldrich, Gillingham, UK; mouse). Secondary antibodies used
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Figure 1. LTP treatment leads to a reduction in cell viability. (A) Cells were treated with a dielectric barrier discharge LTP jet, using 2 SLM helium
flow rate with 0.3% O2 admixture, operated at 6 kV and 30 kHz. Reduction in cell viability was determined by alamarBlue assay (B, C) in BPH-1 and
PC-3 cells and (D, E) in normal and cancer primary epithelial cells at 24, 48, 72 and 96h postexposure.
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included: anti-rabbit IgG HRP-linked (1 : 5000, Cell Signalling
Technology Inc. no. 7074S), and anti-mouse IgG peroxidase
(1 : 5000, Sigma-Aldrich A5906). Staurosporine (1 mM) was used as
a positive control for apoptosis (Cell Signalling Technology Inc. no.
9953). Kaleidoscope protein ladder was used as a marker for all gels
(161-0375, Bio-Rad). Staurosporine (1 mM) was used as a positive
control for apoptosis (Cell Signalling Technology Inc. no. 9953).
The ratio of LC3BII/I band intensity was performed using ImageJ
software (Mount Royal, QC, Canada), with all bands quantified
against b-actin loading control lanes and normalised untreated
controls.
Caspase-Glo 3/7 assay. Cells were treated with LTP and plated
into collagen-coated 96-well plates at a density of 20 000 cells per
well in 100 ml. A further 100 ml of caspase-glo 3/7 detection reagent
(Cat. no. G8090, Promega) was immediately added to each well.
Cells were incubated at 37 1C, with luminescence intensity
(Polarstar Optima, BMG Labtech) recorded at 24 h after treatment.
Based on findings from other results, a reduced set of LTP
exposures was used for this assay.
CellTox necrosis assay. LTP-induced necrosis was quantified
using the CellTox green cytoxicity assay (Cat. no. G8741,
Promega). Cells were treated with LTP and plated into collagen-
coated black-walled 96-well plates at a density of 10 000 cells in
50 ml of media per well. In addition to H2O2 and staurosporine, 2ml
of lysis solution (supplied with assay) was added to necrotic control
wells. Fluorescence intensity was recorded using a plate reader
(Polarstar Optima, BMG Labtech), at excitation/emission wave-
length 485/520 nm, with readings at 2, 4, 8, 12, and 24 h after
treatment. Fluorescence was normalised to untreated wells.
Complementary fluorescence-brightfield merged microscopy
images were also taken (Nikon Eclipse TE300 microscope,  10
objective lens) at the same posttreatment time intervals.
Statistical analysis. All experiments were performed in triplicate,
and results are expressed as the mean with associated s.e., with the
exception of comet assay data, which shows the median DNA
damage value. Plots were constructed and statistical analyses
performed using Prism 6 (GraphPad software, San Diego, CA,
USA). Statistical significance was determined using unpaired
Mann–Whitney test (DNA damage results only) or unpaired
t-test with Welch’s correction (assumes non-equal s.d.) and
displayed on figure plots as *Po0.05, **Po0.01, ***Po0.001,
and ****Po0.0001.
RESULTS
Reduction in cell viability is observed following LTP treatment.
The viability of cells was quantified at 24, 48, 72, and 96 h following
LTP treatment (Figure 1). A reduction in viability in both BPH-1
(Figure 1B) and PC-3 (Figure 1C) cell lines was observed. BPH-1
viability was reduced too20%, whereas viability of PC-3 cells was
reduced to o40%. In addition, reduced cell viability was recorded
in both normal and primary cells (Figure 1D and E), with 30-s LTP
exposure leading to a small decrease in viability and 600-s exposure
reducing cell viability too20%. The positive H2O2 control was less
toxic to both primary samples than the longer LTP exposures (180
and 600 s). The cell lines were more susceptible to 1mM H2O2, (up
to 90% reduction) than primary cells, which only had a B30%
reduction with H2O2 alone. Furthermore, the duration posttreat-
ment had little effect on viability in primary samples, with
comparable results recorded at 24 and 96 h, particularly in the
tumour cells (Figure 1E).
DNA damage is sustained as a result of LTP exposure. LTP-
induced DNA damage was assessed using the alkaline comet
assay, with the percentage of DNA-in-tail recorded for analysis.
Figure 2A and B show the percentage of DNA damage in both
BPH-1 and PC-3 cells, respectively, for various exposure times.
Each dot represents the DNA-in-tail percentage value from
a single cell. Exposures as short as 30 s induced high levels of DNA
damage, with a saturation of damage levels occurring from 180 s.
This concurs with findings in normal and tumour primary cells
(Figure 2C and D). The level of DNA damage from LTP exposure
was found to be consistently comparable to the H2O2 treatment
control, and the level of damage in the tumour-derived primary
sample (Figure 2D) was marginally higher (but statistically
significant, Po0.001) than that recorded for the normal sample
(Figure 2C).
Inhibition of colony-forming capacity as a result of LTP
treatment. Treatment with LTP showed a dose dependent
inhibition of cell recovery in both BPH-1 and PC-3 cells, with
the cancer cell line being more resistant than the benign cell line
(Figure 3A and B). Findings in primary cells showed that treatment
with 600-s LTP reduced the surviving fraction to B20% in both
normal and tumour samples (Figure 3E and F). The tumour cells
appeared significantly more resistant to the shorter 180-s LTP
exposure and to the H2O2 control than the normal cells.
Evaluation of H2O2 formation in cell culture media. Cells in
suspension were treated with LTP for a variety of times before
being analysed for the presence of extracellular H2O2 in the cell
culture media, as an indication of LTP-induced ROS production.
It is well known that H2O2 is extremely toxic to cells
(Bandyopadhyay et al, 1999), even at micromolar concentrations
(Gulden et al, 2010). Figure 3C and D show an increase in the
relative concentrations of H2O2 generated in the culture media
with increasing LTP exposure times for BPH-1 and PC-3 cells.
H2O2 production in PC-3 cells was far lower following LTP
compared with H2O2 control, yet 180 and 600-s LTP exposures in
BPH-1 cells were comparable to H2O2 control. In primary samples,
a treatment time of 180 s yielded luminescence values comparable
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Figure 2. LTP treatment induces high levels of DNA damage in both
prostate cell lines and primary epithelial cells. Cells were treated with
LTP or H2O2 control (1mM). DNA damage levels were measured using
the alkaline comet assay and are represented as the percentage of
DNA-in-tail in (A) BPH-1 and (B) PC-3 cells and in (C) normal and (D)
cancer primary epithelial cells. Each dot represents a single cell, with a
minimum of 100 cells counted for each exposure. Data are expressed
as median±s.e. and are analysed by Mann–Whitney test. All
significance was determined against untreated samples unless
otherwise indicated.
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to 1mM H2O2 positive control in normal cells. An exposure time of
600 s corresponded to approximately two-fold of the concentration
of a 1mM H2O2 positive control in normal cells and three-fold in
cancer cells (Figure 3G and H).
LTP exposure induces different cell death pathways in cells lines
and primary prostate epithelial cells. Our results indicate that
LTP exposure causes necrosis in both BPH-1 and PC-3 cell lines,
as seen in Figure 4A and B. It is clear that PC-3 cells are more
resistant to LTP-induced necrosis than BPH-1 cells. Significantly,
necrotic cell death was also observed in both normal and cancer
prostate primary cells. Figure 4C and D indicate that 180- and
600-s LTP exposures lead to high levels of necrosis compared
with untreated control, with the findings common to both normal
and cancer samples. This was verified by supportive fluorescence
images taken at 4 h after treatment, which highlighted cells
positive for necrosis (green) in 180- and 600-s LTP exposure
wells, whereas staurosporine controls were largely negative at this
time point.
Initially, the levels of necrosis at 2 h posttreatment were
comparable for 180- and 600-s exposures. Cells treated with 600-s
LTP showed a marked time-dependent increase in necrosis,
whereas values for 180-s samples remained approximately
constant. Interestingly, cytopathic effects with the pure H2O2
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Figure 3. LTP treatment leads to reduction in colony-forming efficiency, and high levels of H2O2 in cell culture media. Cells were treated with LTP
or H2O2 control (1mM). Cell recovery was quantified using the colony-forming assays and is represented as surviving fraction posttreatment in (A)
BPH-1 and (B) PC-3 cells and in (E) normal and (F) cancer primary epithelial cells. Immediately following treatment, ROS-Glo H2O2 luminescence
assay (Promega) was performed to ascertain H2O2 levels in the culture media of (C) BPH-1 and (D) PC-3 cells and in (G) normal and (H) cancer
primary epithelial cells (Note the different y axis scales). Data are expressed as mean±s.e., with statistical analysis conducted using unpaired t-test
with Welch’s correction. All significance was determined against untreated samples unless otherwise indicated.
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Figure 4. LTP treatment leads to necrotic cell death in both prostate cell lines and primary epithelial cells. Immediately following LTP treatment,
the CellTox green cytoxicity assay (Promega) was performed to identify cells with comprimised membrane integrity characteristic of necrosis. In all,
1mM H2O2, 1 mM staurosporine, and cell lysing agent (supplied with assay) were used as controls. Fluorescence intensity was quantified at 2, 4, 8,
12, and 24h following treatment and normalised to untreated control wells in (A) BPH-1 and (B) PC-3 cell lines and in (C) normal and (D) cancer
primary epithelial cells. Data are expressed as mean±s.e. Supporting fluorescence microscopy images (10 magnification) taken at 4 h after
treatment are also shown for each cell type.
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control did not present until around 12–24 h after treatment.
Likewise, the staurosporine treatment induced necrosis only at
24 h, indicative of late-stage apoptosis.
In addition to necrosis, a proportion of BPH-1 cells also
underwent apoptosis following LTP exposure as verified by
western blotting for the presence of cleaved-PARP, whereas PC-3
cells did not (Figure 5A and B). Primary cells treated with LTP did
not undergo apoptosis (Figure 5C and D). This was further
confirmed by assessment of caspase 3 and 7 activity in primary
samples (Caspase-glo 3/7 assay, Promega), where only staurospor-
ine-treated positive control cells showed positive expression
(Figure 5E). Indeed, LTP-treated primary cells showed apoptotic
activity levels below those of untreated control, further verifying
that cell death following LTP exposure occurs through necrosis and
not apoptosis.
In addition to apoptosis and necrosis, another cellular response
to stress is autophagy, which can serve as a protective mechanism,
but also results in cell death. Quantitation of LC3 II/I band
intensity revealed that, by 24 h posttreatment, a more than two-
and a more than four-fold increase (over untreated controls) was
present in the cancer and normal samples, respectively, indicating
that an autophagic response occurred following LTP exposure
(Figure 5C and D).
DISCUSSION
In this work, we have shown that treatment with LTP causes DNA
damage, a reduction in both cell viability and recovery, and
ultimately necrotic cell death in normal and cancer primary
prostate epithelial cells. The results indicate that LTP-induced
H2O2 in the culture media is a likely facilitator of these effects. We
also observed that, unlike primary cells and the PC-3 cell line,
BPH-1 cells also die through apoptotic mechanisms following
plasma treatment (Figure 6). Our findings in primary cells
highlight the potential of LTP as an alternative to, or for use in
conjunction with, other existing treatments for organ-confined
prostate cancer. Furthermore, the differential cell death response
between cell lines and primary cells stresses the need to study
clinically relevant models in order to gain insight into the potential
patient response.
LTP exposure is known to cause cytotoxic effects in cells via the
delivery of RONS to the liquid environment (Ahn et al, 2014; Ishaq
2 h
4 h
8 h
12 h
24 h
0 30 18
0
60
0
H
2O
2
St
au
ro
0 30 18
0
60
0
H
2O
2
St
au
ro
0 30 18
0
60
0
H
2O
2
St
au
ro
0 30 18
0
60
0
H
2O
2
St
au
ro
C-PARP
-Actin
C-PARP
-Actin
C-PARP
-Actin
C-PARP
-Actin
C-PARP
-Actin
C-PARP
-Actin
C-PARP
-Actin
C-PARP
-Actin
C-PARP
-Actin
C-PARP
C-PARP
LC3B
1.00 0.80 1.50 1.11 0.97 9.92
1.00 0.96 0.94 2.18 1.44 4.54
1.00 0.97 1.21 1.07 1.08 1.79
1.00 1.50 1.37 1.61 1.42 2.03
1.00 0.86 0.94 0.87 0.95 1.63
1.00 0.56 0.58 0.61 0.63 1.40
1.00 1.77 2.66 2.16 3.11 14.351.00 1.11 3.08 4.22 2.89 21.27
-Actin
-Actin
C-PARP
LC3B
-Actin
C-PARP
LC3B
-Actin
C-PARP
LC3B
-Actin
C-PARP
LC3B
-Actin
C-PARP
LC3B
R
el
at
ive
 lu
m
in
es
ce
nc
e 
un
its
 (R
LU
)
50 000
40 000
30 000
20 000
10 000
–10 000
–20 000
0
-Actin
C-PARP
LC3B
-Actin
C-PARP
LC3B
-Actin
Normal
Cancer
2 h
4 h
8 h
12 h
24 h
2 h
4 h
8 h
24 h
2 h
4 h
8 h
24 h
Plasma exposure (s) / control
Stauro6001800
Figure 5. Cell death mechanisms following LTP treatment vary
between cell types. Following treatment with LTP, 1mM H2O2, or 1 mM
staurosporine, protein lysates were harvested. (A) BPH-1 and (B) PC-3
cell line lysates were probed for apoptosis (C-PARP) by western
blotting. (C) Normal and (D) cancer primary epithelial lysates were
probed for apoptosis (C-PARP) and also autophagy (LC3B I/II). b-Actin
was used as a loading control throughout. Band intensity quantification
was performed using the ImageJ software. Further analysis of apoptotic
activity was conducted in (E) primary epithelial cells using Caspase-glo
3/7 assay (Promega). Immediately following treatment, caspase-glo 3/7
detection reagent was added to all wells, and luminescence intensity
was quantified at 24 h. Readings were normalised to untreated control
and are expressed as mean±s.e.
Treatment
Primary cells
Cell lines
Necrosis
Apoptosis
Autophagy
Cell
Figure 6. Overview of cellular response mechanism following LTP
treatment. As a result of exposure to LTP, cells were observed to
undergo (or a combination of) autophagy, apoptosis or necrosis. The
relative proportions of, and differences between, cell lines (red arrows)
and primary epithelial cells (green arrows) that exhibit these
phenomena is emphasised. Adapted from Kepp et al (2011).
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et al, 2014; Ma et al, 2014). Our results indicate that 180-s LTP
treatment of prostate primary cells leads to H2O2 concentrations
approximately equal to that of a 1mM H2O2 control. Additionally,
LTP exposure of 600 s produced statistically significant H2O2
readings two- to three-fold to those of the control. Interestingly,
following exposure to LTP, the levels of H2O2 recorded in the
tumour cells were found to be lower generally than those from the
normal cells, resulting in an enhanced colony recovery following
treatment at 30- and 180-s LTP treatment times but not at the
longest exposure of 600 s. This is in keeping with recent data,
suggesting that cancer cells have the ability to quench the effects of
ROS more effectively than normal cells (Diehn et al, 2009; Gorrini
et al, 2013). Despite this, cell viability is still strongly reduced
following LTP treatments of 180 and 600 s, indicating that any
RONS produced initially in the culture medium remain strongly
damaging to the primary cells at increased time periods
postexposure. In contrast to data from the proof-of-principle
study on prostate cell lines (Figure 1B and C), the primary samples
appear far more resistant to the H2O2 control, yet the reduction in
viability as a result of LTP exposure is comparable between the
different samples (Figure 2C and D). This suggests that the
enhanced effect of the plasma is likely to be due to
a cumulative effect on the cells of a multitude of reactive species
produced in the plasma (the presence of atomic oxygen in the
plasma core was verified by optical emission spectroscopy,
Supplementary Figure S1), and/or additional plasma components
such as electric fields, charges, and UV radiation (Graves, 2012;
Kang et al, 2014), rather than just solely due to H2O2. This may
also make it unlikely for cancer cells to become resistant to
treatment, as increased tolerance to a particular reactive species
would not protect against the perceived multi-faceted action of
LTP. Because of the added presence of reactive nitrogen species
produced by some LTPs (Cheng et al, 2014; Gibson et al, 2014),
this may also present an advantage over radiotherapy, which relies
heavily on ROS alone (Palacios et al, 2013), and over PDT, which
relies predominantly on the single reactive species SDO for its
cytotoxic effect (Sharman et al, 1999).
A contribution of the cell culture media to the observed effects
cannot be discounted. We measured a three-fold increase over
control of H2O2 production after plasma treatment in primary
cells. Yet, we see that, in the BPH-1 cell line, the LTP-treated H2O2
concentrations are broadly similar, and in the PC-3 cell line the
H2O2 concentrations are much lower than the control (Figure 1E
and F). It is known that different cell culture media can produce
different amounts of H2O2 (Promega Technical Services, private
communication). We therefore considered treating all cell types in
a buffered saline solution and re-plating the cells in their optimal
culture media. However, a counter-argument is that this would not
have been physiological (with respect to treating a patient) and that
any cytopathic effect would be likely to be predominantly due to
short-lived reactive species, and the prolonged effects of long-lived
species would be lost. Significantly, both normal and cancer
primary cells used in this study were cultured and treated in
identical media without serum, and so media was not a variable
factor and the results from these cells can be directly compared.
Differences in H2O2 levels were recorded in treated media
containing cells and treated media only. All plasma-treated
samples showed a reduction in H2O2 production in the presence
of cells (vs treated media), suggesting that the cells consume, or
quench, H2O2 in the media (Supplementary Figure S2A). This was
by far the most pronounced in primary cells, where the H2O2 level
following 180-s LTP exposure was reduced by 78% in the presence
of cells. There was far less of a reduction in BPH-1 cells (17%) and
PC-3 cells (41%). It was also found that, by 2 h following treatment,
the levels of H2O2 (induced by either 600-s plasma treatment or
1mM H2O2) were strongly reduced in both normal and tumour
primary cells. This effect was more pronounced in the tumour cells
and demonstrates the strong ROS-quenching capacity of the
primary cells (Supplementary Figure S2B and C). The level of
H2O2 formed by the positive control was further reduced to that of
the untreated cells by 8 h; however, there were still elevated levels
of H2O2 induced by plasma treatment detected at this time point.
We have found that high levels of DNA damage, which is
uniform across all cell types, is inflicted after an LTP exposure of
only 30 s. In addition, a reduction in colony-forming ability
following LTP treatment was observed, as cells treated with 600-s
LTP recovered significantly less than those treated with the H2O2
control. This is despite the DNA damage values between 600 s and
H2O2 control differing by only a few percent across all samples, in
support of the hypothesis that the cytocidal effect of the plasma on
cells is not solely due to H2O2 production. Therefore, in vitro,
retaining the cells in treated media is necessary to realise a strong
anti-proliferative effect (which we investigated and found to be the
case; data not shown), as would be seen in tissues. Other LTP-
based studies report a selective plasma effect (Wang et al, 2013;
Guerrero-Preston et al, 2014), that is, that the plasma preferentially
induces cell death in cancer cells. However, normal and tumour
cell lines studied often originate from different sites or hosts or are
cultured in different media. We observe similar responses in both
primary prostate tumour and normal cells from the same patient,
highlighting the necessity for supporting live imaging, for example,
MRI, for precise targeted tumour ablation in patients (Sullivan and
Crawford, 2009).
Finally, for any progression towards a patient therapy, further
elucidation of the mechanism of LTP-induced cell death is
required. Following a fatal stimulus, cell death can occur broadly
in one of the two ways; apoptosis – a regulated chain of events
involving cell shrinkage, blebbing, and ending with the formation
of apoptotic bodies that retain membrane integrity (Cohen, 1997),
or necrosis – an uncontrolled swelling that leads to membrane
rupture and spillage of the cell contents into the surrounding
environment, provoking an inflammatory response (Casiano et al,
1998). It is clear from our results that primary cells rapidly undergo
necrosis, in the almost complete absence of apoptosis. A major
advantage of this is that necrotic cell death has the potential to
promote immune-activation against tumour cells (Melcher et al,
1999). In contrast, apoptotic cell death has been observed to
promote an immune-suppressive environment (Voll et al, 1997),
allowing tumour cells to evade detection by the immune system
(Gregory and Pound, 2010). Our findings were common to both
normal and cancer primary sample with some subtle differences.
Marginally higher levels of necrosis were observed in the cancer
cells following 600-s exposure, yet both samples show almost
identical recovery from this treatment (20% surviving fraction).
Both normal and cancer cells treated with long LTP exposures (180
and 600 s) undergo autophagy: a completely novel finding in LTP
studies on human cells. This may be a survival process for cells that
do not undergo necrosis. Our observation of higher levels of
autophagy in primary normal cells may be attributed to the
hypothesis that normal cells have a higher ROS-threshold tolerance
than cancer cells (Gorrini et al, 2013).
Although this study argues that LTP could become a potential
focal therapy for localised PCa, it remains possible that a reduction
in metastatic tumour volume could be observed after treatment
with LTP, as a result of necrotic cell death and its associated
immune response as outlined earlier. Referred to as spontaneous
regression, this response has been documented following necrosis-
inducing thermal ablation treatments for other cancers (Sanchez-
Ortiz et al, 2003; Kim et al, 2008; Chu and Dupuy, 2014), but the
mechanisms responsible are largely unknown. Nevertheless, a
proportion of cells survive LTP treatment and are able to
proliferate following exposure to LTP, as demonstrated by their
residual colony-forming capacity. The reasons for this must be
determined and may potentially be overcome by manipulation and
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optimisation of the plasma parameters (Cheng et al, 2014) and/or
pretreatment with a sensitising agent (Frame et al, 2013).
Finally, the differences in response we have observed between
prostate cell lines and primary cells, particularly in terms of the
mechanism of cell death, highlights the importance of studying
primary cultures in order to gain an insight into patient efficacy.
More specifically, the cell death mechanisms that are triggered
following administration of LTP should be elucidated in close-to-
patient models.
CONCLUSIONS
In summary, we have clearly demonstrated the potential of LTP
as a future therapy option for localised prostate cancer. Through
the formation of reactive species (H2O2 and more than likely also
others, e.g., OH, O2
 ) in cell culture media, we observed high
levels of DNA damage in primary cells cultured directly from
patient tissues, together with reduction in cell viability and
colony-forming ability. These ultimately lead to necrotic cell
death in both normal and tumour samples. However, further
optimisation of the LTP operational parameters needs to be
conducted, in order to kill the proportion of cells that remain
viable after treatment. In addition, although we have previously
outlined a potential approach (Hirst et al, 2014b), the feasibility
of physically treating patients who have PCa with LTP has yet to
be established. This would require some modification of the LTP
device itself to deliver the LTP to the tumour bed, sparing normal
tissues, perhaps employing existing apparatus for cryotherapy
and/or brachytherapy.
We believe that with appropriate imaging techniques to facilitate
accurate tumour targeting and spare normal tissues, the multi-
faceted action of LTP will provide advantages over other focal
therapies. More specifically, therapies such as PDT relies on SDO
production to destroy cells; plasmas are known to be able produce a
multitude of RONS that are toxic to cells. Given that LTPs can be
propagated from tubes o100mm in diameter (Kim et al, 2011), we
believe that LTP therapy could be more targeted than radiotherapy
and more controlled than ice-ball formation in cryotherapy. LTP
would not require additional equipment such as the warming
catheters used in cryosurgery. Moreover, LTP treatment should
prove far more cost-effective than existing treatments.
ACKNOWLEDGEMENTS
This work was part-funded by the Wellcome Trust: ref: 097829/Z/
11/A and the UK EPSRC through a Career Acceleration Fellowship:
EP/H003797/1 (O’Connell) and Manufacturing the Future grant:
EP/K018388/1 (all to O’Connell). We acknowledge funding from
Yorkshire Cancer Research: YCR – Y257PA (Frame, Maitland). We
thank P Roberts (University of York, UK) for his assistance with the
graphic design used in this paper, A West (University of York, UK)
for his assistance with optical emission spectroscopy, and also all
the patients and urology surgeons L Coombes, G Cooksey, and
J Hetherington (Castle Hill Hospital, Cottingham, UK).
REFERENCES
Ahn HJ, Kim KI, Hoan NN, Kim CH, Moon E, Choi KS, Yang SS, Lee JS
(2014) Targeting cancer cells with reactive oxygen and nitrogen species
generated by atmospheric-pressure air plasma. PLoS One 9: e86173.
Bandyopadhyay U, Das D, Banerjee RK (1999) Reactive oxygen species:
oxidative damage and pathogenesis. Curr Sci 77: 658–666.
Casiano CA, Ochs RL, Tan EM (1998) Distinct cleavage products of nuclear
proteins in apoptosis and necrosis revealed by autoantibody probes. Cell
Death Differ 5: 183–190.
Chang JW, Kang SU, Shin YS, Kim KI, Seo SJ, Yang SS, Lee JS, Moon E, Baek
SJ, Lee K, Kim CH (2014) Non-thermal atmospheric pressure plasma
induces apoptosis in oral cavity squamous cell carcinoma: Involvement of
DNA-damage-triggering sub-G(1) arrest via the ATM/p53 pathway
Arch Biochem Biophys 545: 133–140.
Chen MJ, Weltman E, Hanriot RM, Luz FP, Cecilio PJ, Da Cruz JC,
Moreira FR, Santos AS, Martins LC, Nadalin W (2007) Intensity
modulated radiotherapy for localized prostate cancer: rigid compliance
to dose-volume constraints as a warranty of acceptable toxicity?
Radiat Oncol 2: 6.
Cheng X, Sherman J, Murphy W, Ratovitski E, Canady J, Keidar M (2014)
The effect of tuning cold plasma composition on glioblastoma cell
viability. PLoS One 9: e98652.
Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological
mechanisms and advances in therapy. Nat Rev Cancer 14: 199–208.
Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326(Pt 1):
1–16.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective
identification of tumorigenic prostate cancer stem cells. Cancer Res 65:
10946–10951.
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS,
Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G,
Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL,
Clarke MF (2009) Association of reactive oxygen species levels and
radioresistance in cancer stem cells. Nature 458: 780–783.
Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D,
Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A,
Mccartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, Van Der
Meulen J, Villers A, Willis S, Ahmed HU (2014) Focal therapy: patients,
interventions, and outcomes-a report from a consensus meeting. Eur Urol
67(4): 771–777.
Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM, Jones GD,
Meuth M, Bristow RG, Maitland NJ (2013) HDAC inhibitor confers
radiosensitivity to prostate stem-like cells. Br J Cancer 109: 3023–3033.
Francipane MG, Alea MP, Lombardo Y, Todaro M, Medema JP, Stassi G
(2008) Crucial role of interleukin-4 in the survival of colon cancer stem
cells. Cancer Res 68: 4022–4025.
Gibson AR, Mccarthy HO, Ali AA, O’connell D, Graham WG (2014)
Interactions of a non-thermal atmospheric pressure plasma effluent with
PC-3 prostate cancer cells. Plasma Process Polym 11(12): 1142–1149.
Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an
anticancer strategy. Nat Rev Drug Discov 12: 931–947.
Graves DB (2012) The emerging role of reactive oxygen and nitrogen species
in redox biology and some implications for plasma applications to
medicine and biology. J Phys D Appl Phys 45: 263001.
Graves DB (2014) Low temperature plasma biomedicine: a tutorial reviewa.
Phys Plasmas 21: 080901.
Gregory CD, Pound JD (2010) Microenvironmental influences of apoptosis
in vivo and in vitro. Apoptosis 15: 1029–1049.
Guerrero-Preston R, Ogawa T, Uemura M, Shumulinsky G, Valle BL, Pirini F,
Ravi R, Sidransky D, Keidar M, Trink B (2014) Cold atmospheric plasma
treatment selectively targets head and neck squamous cell carcinoma cells.
Int J Mol Med 34: 941–946.
Gulden M, Jess A, Kammann J, Maser E, Seibert H (2010) Cytotoxic potency
of H2O2 in cell cultures: impact of cell concentration and exposure time.
Free Radic Biol Med 49: 1298–1305.
Hirst AM, Frame FM, Maitland NJ, O’connell D (2014a) Low temperature
plasma causes double-strand break DNA damage in primary epithelial
cells cultured from a human prostate tumor. Plasma Sci IEEE Trans
42(10): 2740–2741.
Hirst AM, Frame FM, Maitland NJ, O’connell D (2014b) Low temperature
plasma: a novel focal therapy for localized prostate cancer? Biomed Res Int
2014: 878319.
Ishaq M, Kumar S, Varinli H, Han ZJ, Rider AE, Evans MD, Murphy AB,
Ostrikov K (2014) Atmospheric gas plasma-induced ROS production
activates TNF-ASK1 pathway for the induction of melanoma cancer cell
apoptosis. Mol Biol Cell 25: 1523–1531.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global
cancer statistics. CA Cancer J Clin 61: 69–90.
BRITISH JOURNAL OF CANCER Plasma treatment in prostate cancer
1544 www.bjcancer.com |DOI:10.1038/bjc.2015.113
Jones JS (2011) Radiorecurrent prostate cancer: an emerging and largely
mismanaged epidemic. Eur Urol 60: 411–412.
Kang SU, Cho JH, Chang JW, Shin YS, Kim KI, Park JK, Yang SS, Lee JS,
Moon E, Lee K, Kim CH (2014) Nonthermal plasma induces head and
neck cancer cell death: the potential involvement of mitogen-activated
protein kinase-dependent mitochondrial reactive oxygen species. Cell
Death Dis 5: e1056.
Kasivisvanathan V, Emberton M, Ahmed HU (2013) Focal therapy for
prostate cancer: rationale and treatment opportunities. Clin Oncol
(R Coll Radiol) 25: 461–473.
Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S, Ravi R,
Guerrero-Preston R, Trink B (2011) Cold plasma selectivity and the
possibility of a paradigm shift in cancer therapy. Br J Cancer 105: 1295–1301.
Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G (2011) Cell death assays
for drug discovery. Nat Rev Drug Discov 10: 221–237.
Kim H, Park BK, Kim CK (2008) Spontaneous regression of pulmonary and
adrenal metastases following percutaneous radiofrequency ablation of a
recurrent renal cell carcinoma. Korean J Radiol 9: 470–472.
Kim JY, Ballato J, Foy P, Hawkins T, Wei Y, Li J, Kim SO (2011) Apoptosis of
lung carcinoma cells induced by a flexible optical fiber-based cold
microplasma. Biosens Bioelectron 28: 333–338.
Knake N, Niemi K, Reuter S, Schulz-Von Der Gathen V, Winter J (2008)
Absolute atomic oxygen density profiles in the discharge core of a
microscale atmospheric pressure plasma jet. Appl Phys Lett 93: 131503–
131503.
Krzykawska-Serda M, Dabrowski JM, Arnaut LG, Szczygiel M, Urbanska K,
Stochel G, Elas M (2014) The role of strong hypoxia in tumors after
treatment in the outcome of bacteriochlorin-based photodynamic therapy.
Free Radic Biol Med 73C: 239–251.
Lips IM, Dehnad H, Van Gils CH, Boeken Kruger AE, Van Der Heide UA,
Van Vulpen M (2008) High-dose intensity-modulated radiotherapy for
prostate cancer using daily fiducial marker-based position verification:
acute and late toxicity in 331 patients. Radiat Oncol 3: 15.
Ma Y, Ha CS, Hwang SW, Lee HJ, Kim GC, Lee KW, Song K (2014) Non-
thermal atmospheric pressure plasma preferentially induces apoptosis in
p53-mutated cancer cells by activating ROS stress-response pathways.
PLoS One 9: e91947.
Melcher A, Gough M, Todryk S, Vile R (1999) Apoptosis or necrosis for
tumor immunotherapy: what’s in a name? J Mol Med (Berl) 77: 824–833.
Murakami T, Niemi K, Gans T, O’connell D, Graham WG (2013) Chemical
kinetics and reactive species in atmospheric pressure helium-oxygen
plasmas with humid-air impurities. Plasma Sources Sci Technol 22:
015003.
Niemi K, O’connell D, Oliveira DE, Joyeux N, Nahon D, Booth L, Gans, T. JP
(2013) Absolute atomic oxygen and nitrogen densities in radio-frequency
driven atmospheric pressure cold plasmas: synchrotron vacuum ultra-
violet high-resolution Fourier-transform absorption measurements. Appl
Phys Lett 103: 034102.
Ninomiya K, Ishijima T, Imamura M, Yamahara T, Enomoto H, Takahashi K,
Tanaka Y, Uesugi Y, Shimizu N (2013) Evaluation of extra- and
intracellular OH radical generation, cancer cell injury, and apoptosis
induced by a non-thermal atmospheric-pressure plasma jet. J Phys D Appl
Phys 46: 425401.
Palacios DA, Miyake M, Rosser CJ (2013) Radiosensitization in prostate
cancer: mechanisms and targets. BMC Urol 13: 4.
Plewa JM, Yousfi M, Frongia C, Eichwald O, Ducommun B, Merbahi N,
Lobjois V (2014) Low-temperature plasma-induced antiproliferative
effects on multi-cellular tumor spheroids. N J Phys 16: 043027.
Robert E, Vandamme M, Brulle´ L, Lerondel S, Le Pape A, Sarron V, Rie`s D,
Darny T, Dozias S, Collet G, Kieda C, Pouvesle JM (2013) Perspectives of
endoscopic plasma applications. Clin Plasma Med 1: 8–16.
Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG (2003) Spontaneous
regression of pulmonary metastases from renal cell carcinoma after radio
frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 170:
178–179.
Sharman WM, Allen CM, Van Lier JE (1999) Photodynamic therapeutics:
basic principles and clinical applications. Drug Discov Today 4: 507–517.
Sousa JS, Niemi K, Cox LJ, Algwari QT, Gans T, O’connell D (2011) Cold
atmospheric pressure plasma jets as sources of singlet delta oxygen for
biomedical applications. J Appl Phys 109: 123302.
Sturmey RG, Hawkhead JA, Barker EA, Leese HJ (2009) DNA damage and
metabolic activity in the preimplantation embryo. Hum Reprod 24: 81–91.
Sullivan KF, Crawford ED (2009) Targeted focal therapy for prostate cancer: a
review of the literature. Ther Adv Urol 1: 149–159.
Vandamme M, Robert E, Lerondel S, Sarron V, Ries D, Dozias S, Sobilo J,
Gosset D, Kieda C, Legrain B, Pouvesle JM, Pape AL (2012) ROS
implication in a new antitumor strategy based on non-thermal plasma.
Int J Cancer 130: 2185–2194.
Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I (1997)
Immunosuppressive effects of apoptotic cells. Nature 390: 350–351.
Wagenaars E, Gans T, O’connell D, Niemi K (2012) Two-photon
absorption laser-induced fluorescence measurements of atomic nitrogen
in a radio-frequency atmospheric-pressure plasma jet. Plasma Sources Sci
Technol 21: 042002.
Wang M, Holmes B, Cheng X, Zhu W, Keidar M, Zhang LG (2013) Cold
atmospheric plasma for selectively ablating metastatic breast cancer cells.
PLoS One 8: e73741.
Waskoenig J, Niemi K, Knake N, Graham LM, Reuter S, Schulz-Von Der Gathen V,
Gans T (2010) Atomic oxygen formation in a radio-frequency driven
micro-atmospheric pressure plasma jet. Plasma Sources Sci Technol
19: 045018.
Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and
nitrogen species: role in inflammatory disease and progression to cancer.
Biochem J 313(Pt 1): 17–29.
Woo JA, Chen LN, Bhagat A, Oermann EK, Kim JS, Moures R, Yung T, Lei S,
Collins BT, Kumar D, Suy S, Dritschilo A, Lynch JH, Collins SP (2014)
Clinical characteristics and management of late urinary symptom flare
following stereotactic body radiation therapy for prostate cancer. Front
Oncol 4: 122.
This work is licensed under the Creative
CommonsAttribution 4.0 International License.
To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/
Plasma treatment in prostate cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.113 1545
